Surveillance of Humira Injection in Korean Patients

* Adult patients (19 years and above) with one of the following indications: * Moderately to severely active rheumatoid arthritis or * active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate or * severe active ankylosing spondylitis who have had an inadequate response to conventional therapy or * severely active Crohn's disease who have had no response, intolerance or contraindication to corticosteroid therapy or immunosuppressants or * moderately to severely active psoriasis patients who have had no response, have intolerance or have contraindication to systemic therapies including cyclosporine, methotrexate or photochemotherapy (PUVA). * Patients who give verbal or written authorization to use their personal and health data.

\- Patients with known hypersensitivity to adalimumab or any of its excipients.